267 related articles for article (PubMed ID: 31344424)
1. Enhanced anti-angiogenic effects of bevacizumab in glioblastoma treatment upon intranasal administration in polymeric nanoparticles.
Sousa F; Dhaliwal HK; Gattacceca F; Sarmento B; Amiji MM
J Control Release; 2019 Sep; 309():37-47. PubMed ID: 31344424
[TBL] [Abstract][Full Text] [Related]
2. Effect of nanoencapsulation using poly (lactide-co-glycolide) (PLGA) on anti-angiogenic activity of bevacizumab for ocular angiogenesis therapy.
Zhang XP; Sun JG; Yao J; Shan K; Liu BH; Yao MD; Ge HM; Jiang Q; Zhao C; Yan B
Biomed Pharmacother; 2018 Nov; 107():1056-1063. PubMed ID: 30257317
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Caspase-Mediated Abrogation of Autophagy by Temozolomide-Loaded and Panitumumab-Conjugated Poly(lactic-
Banstola A; Duwa R; Emami F; Jeong JH; Yook S
Mol Pharm; 2020 Nov; 17(11):4386-4400. PubMed ID: 33079558
[TBL] [Abstract][Full Text] [Related]
4. Chlorotoxin modified morusin-PLGA nanoparticles for targeted glioblastoma therapy.
Agarwal S; Mohamed MS; Mizuki T; Maekawa T; Sakthi Kumar D
J Mater Chem B; 2019 Oct; 7(39):5896-5919. PubMed ID: 31423502
[TBL] [Abstract][Full Text] [Related]
5. Preparation of Cholera Toxin Subunit B Functionalized Nanoparticles for Targeted Therapy of Glioblastoma.
Guan J; Qian J; Zhan C
Methods Mol Biol; 2020; 2059():207-212. PubMed ID: 31435923
[TBL] [Abstract][Full Text] [Related]
6. A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles.
Sousa F; Cruz A; Fonte P; Pinto IM; Neves-Petersen MT; Sarmento B
Sci Rep; 2017 Jun; 7(1):3736. PubMed ID: 28623267
[TBL] [Abstract][Full Text] [Related]
7. Paclitaxel/methotrexate co-loaded PLGA nanoparticles in glioblastoma treatment: Formulation development and in vitro antitumor activity evaluation.
Madani F; Esnaashari SS; Bergonzi MC; Webster TJ; Younes HM; Khosravani M; Adabi M
Life Sci; 2020 Sep; 256():117943. PubMed ID: 32531377
[TBL] [Abstract][Full Text] [Related]
8. Verteporfin-Loaded Polymeric Microparticles for Intratumoral Treatment of Brain Cancer.
Shah SR; Kim J; Schiapparelli P; Vazquez-Ramos CA; Martinez-Gutierrez JC; Ruiz-Valls A; Inman K; Shamul JG; Green JJ; Quinones-Hinojosa A
Mol Pharm; 2019 Apr; 16(4):1433-1443. PubMed ID: 30803231
[TBL] [Abstract][Full Text] [Related]
9. Intranasal delivery of cancer-targeting doxorubicin-loaded PLGA nanoparticles arrests glioblastoma growth.
Chung K; Ullah I; Kim N; Lim J; Shin J; Lee SC; Jeon S; Kim SH; Kumar P; Lee SK
J Drug Target; 2020 Jul; 28(6):617-626. PubMed ID: 31852284
[TBL] [Abstract][Full Text] [Related]
10. Chitosan coated nanoparticles for efficient delivery of bevacizumab in the posterior ocular tissues via subconjunctival administration.
Pandit J; Sultana Y; Aqil M
Carbohydr Polym; 2021 Sep; 267():118217. PubMed ID: 34119171
[TBL] [Abstract][Full Text] [Related]
11. Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI.
Cho HR; Kumari N; Thi Vu H; Kim H; Park CK; Choi SH
Sci Rep; 2019 Jul; 9(1):11085. PubMed ID: 31366997
[TBL] [Abstract][Full Text] [Related]
12. 'Dendrimer-Cationized-Albumin' encrusted polymeric nanoparticle improves BBB penetration and anticancer activity of doxorubicin.
Muniswamy VJ; Raval N; Gondaliya P; Tambe V; Kalia K; Tekade RK
Int J Pharm; 2019 Jan; 555():77-99. PubMed ID: 30448308
[TBL] [Abstract][Full Text] [Related]
13. Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications.
Liu J; Zhang X; Li G; Xu F; Li S; Teng L; Li Y; Sun F
Int J Nanomedicine; 2019; 14():8819-8834. PubMed ID: 31819410
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral VEGF nanotrapper reduces gliobastoma vascularization and tumor cell mass.
Sousa F; Costa-Pereira AI; Cruz A; Ferreira FJ; Gouveia M; Bessa J; Sarmento B; Travasso RDM; Mendes Pinto I
J Control Release; 2021 Nov; 339():381-390. PubMed ID: 34592385
[TBL] [Abstract][Full Text] [Related]
15. Synergistic targeting tenascin C and neuropilin-1 for specific penetration of nanoparticles for anti-glioblastoma treatment.
Kang T; Zhu Q; Jiang D; Feng X; Feng J; Jiang T; Yao J; Jing Y; Song Q; Jiang X; Gao X; Chen J
Biomaterials; 2016 Sep; 101():60-75. PubMed ID: 27267628
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus loaded chitosan functionalized poly (lactic-co-glycolic acid) (PLGA) nanoparticles for potential treatment of age-related macular degeneration.
Suri R; Neupane YR; Mehra N; Nematullah M; Khan F; Alam O; Iqubal A; Jain GK; Kohli K
Int J Biol Macromol; 2021 Nov; 191():548-559. PubMed ID: 34536476
[TBL] [Abstract][Full Text] [Related]
17. Anti-Angiogenics: Their Role in the Treatment of Glioblastoma.
Winkler F; Osswald M; Wick W
Oncol Res Treat; 2018; 41(4):181-186. PubMed ID: 29562225
[TBL] [Abstract][Full Text] [Related]
18. Esterase-responsive and size-optimized prodrug nanoparticles for effective intracranial drug delivery and glioblastoma treatment.
Ye Z; Gao L; Cai J; Wang Y; Li Y; Tong S; Yan T; Sun Q; Qi Y; Xu Y; Jiang H; Zhang S; Zhao L; Zhang S; Chen Q
Nanomedicine; 2022 Aug; 44():102581. PubMed ID: 35811067
[TBL] [Abstract][Full Text] [Related]
19. Development of transferrin-modified poly(lactic-co-glycolic acid) nanoparticles for glioma therapy.
Mao J; Meng X; Zhao C; Yang Y; Liu G
Anticancer Drugs; 2019 Jul; 30(6):604-610. PubMed ID: 30855310
[TBL] [Abstract][Full Text] [Related]
20. Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.
Castro BA; Flanigan P; Jahangiri A; Hoffman D; Chen W; Kuang R; De Lay M; Yagnik G; Wagner JR; Mascharak S; Sidorov M; Shrivastav S; Kohanbash G; Okada H; Aghi MK
Oncogene; 2017 Jun; 36(26):3749-3759. PubMed ID: 28218903
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
